Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 7Gastrointestinal 5Thoracic 4NET 3Gynecologic 2Genitourinary 2CNS 2Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 2Diarrhea 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Octreotide × Genitourinary × Clear all
NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

NCT00510224 2013-12-11

Sandostatin for Patients With Androgen Independent Prostate Cancer

University of California, San Francisco

Phase 2 Terminated
13 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡